⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ROIV News
Roivant Sciences Ltd. Common Shares
Form 8-K/A
sec.gov
ROIV
Form 8-K
sec.gov
ROIV
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
globenewswire.com
ROIVW
ABUS
ROIV
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
globenewswire.com
ABUS
ROIV
MRNA
Form 8-K
sec.gov
ROIV
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
globenewswire.com
ROIV
ROIVW
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
globenewswire.com
ROIV
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
globenewswire.com
ROIV
ROIVW
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
globenewswire.com
ROIV
ROIVW
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
globenewswire.com
IMVT
ROIV